- Home
- MQT vs GALT Comparison
MQT vs GALT Comparison
Compare MQT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- GALT
- Stock Information
- Founded
- MQT 1992
- GALT 2000
- Country
- MQT United States
- GALT United States
- Employees
- MQT N/A
- GALT N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- GALT Health Care
- Exchange
- MQT Nasdaq
- GALT Nasdaq
- Market Cap
- MQT 207.5M
- GALT 232.3M
- IPO Year
- MQT N/A
- GALT N/A
- Fundamental
- Price
- MQT $9.51
- GALT $3.79
- Analyst Decision
- MQT
- GALT Strong Buy
- Analyst Count
- MQT 0
- GALT 3
- Target Price
- MQT N/A
- GALT $6.00
- AVG Volume (30 Days)
- MQT 52.5K
- GALT 287.5K
- Earning Date
- MQT 01-01-0001
- GALT 08-14-2025
- Dividend Yield
- MQT 4.60%
- GALT N/A
- EPS Growth
- MQT N/A
- GALT N/A
- EPS
- MQT N/A
- GALT N/A
- Revenue
- MQT N/A
- GALT N/A
- Revenue This Year
- MQT N/A
- GALT N/A
- Revenue Next Year
- MQT N/A
- GALT N/A
- P/E Ratio
- MQT N/A
- GALT N/A
- Revenue Growth
- MQT N/A
- GALT N/A
- 52 Week Low
- MQT $8.59
- GALT $0.73
- 52 Week High
- MQT $10.67
- GALT $4.41
- Technical
- Relative Strength Index (RSI)
- MQT 47.47
- GALT 66.13
- Support Level
- MQT $9.53
- GALT $3.50
- Resistance Level
- MQT $9.65
- GALT $4.20
- Average True Range (ATR)
- MQT 0.06
- GALT 0.31
- MACD
- MQT 0.00
- GALT -0.03
- Stochastic Oscillator
- MQT 51.72
- GALT 53.31
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.